Study Title
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma (NCT01712490)
Trial Description
This open-label, randomized, 2-arm, multicenter, phase III study has the primary objective of comparing the modified progression-free survival (mPFS) obtained with brentuximab vedotin (Adcetris®) plus AVD (doxorubicin [Adriamycin], vinblastine, and dacarbazine; abbreviated A+AVD) versus that obtained with ABVD (doxorubicin,bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma (HL).
This trial is sponsored by Millennium Pharmaceuticals/Seattle Genetics. [1]
Study Data
- Condition: Hodgkin Lymphoma
- Interventions:
- Drugs used in this trial
- Brentuximab vedotin (Adcetris®; Seattle Genetics, Inc
- Doxorubicin (Adriamycin®; Pfizer/Doxil®; TTY Bio pharmacy Company Limited)
- Bleomycin (Generic; Teva Pharmaceuticals USA)
- Vinblastine (Generic; APP Pharmaceuticals, LLC)
- Dacarbazine (DTIC-Dome®; Bayer Pharmaceuticals Corporation)
- Drugs used in this trial
- Phase: III
- Estimated Enrollment: 1334
- Start: November 2012
- Estimated Completion: March 2020
- Last verified: August 2017
Study Schematic
Click here to Return to Drug map
Last Editorial review: October 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015-2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.
